Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based ADC Biotechnology has announced the development of a production technology for the drug production process of its new antibody for cancer treatment.
Subscribe to our email newsletter
The company has received funds worth £450,000 from Finance Wales, Acceleris, Welsh Government and Denbighshire County Council, which would support its entry into the next phase of development, dailypost.co.uk reported.
The production technology lays emphasis on manufacturing antibody-drug conjugates (ADCs) that target tumour cells directly and is devoid of side effects that are commonly seen in chemotherapy.
Business Post quoted ADC Biotechnology CEO Charlie Johnson saying that their technology would help in efficient and cost effective manufacture of new antibody-based drugs by many pharmaceutical firms.
"Increasing the availability of affordable cancer drugs is one of the key challenges we face today and with drug production becoming ever more complex, technologies that promote faster, safer and more cost effective development of exciting new therapies are vital," Johnson added.